To cite this paper use one of the standards below:
CASE PRESENTATION
A 37-years-old female patient with highly active relapsing-remitting multiple sclerosis (RRMS) was admitted for Alemtuzumab treatment. The formal protocol of 12mg for five days with 1g of methylprednisolone daily for the first three days plus concomitantly acyclovir, diphenhydramine and acetaminophen (< 4g daily) was performed.
Upon the third day of infusion an unexpected rising of her liver function tests was detected. Basal ALT raised from 20 U/L to 1441 U/L on day three, with an AST of 522 U/L, ALP of 119 U/L, GGT of 433 U/L and bilirubin of 0,5 mg/dL. There were no signs of acute liver failure such as encephalopathy, coagulopathy, hepatomegaly or hepatorenal syndrome. Serologies were negative (hepatitis A, B and C antibodies, cytomegalovirus and Ebstein-Barr virus IgM). Antinuclear, antimitochondrial, anti-LKM1 and anti-smooth muscle antibodies were negative.
The Gastroenterology team was consulted and a drug induced liver injury (DILI) associated with Alemtuzumab was suspected. The Roussel Uclaf Causality Assessment Method (RUCAM) score was six, making DILI “probable”. Alemtuzumab was definitely interrupted at the fourth day of treatment, coinciding with a drop in ALT from 440 U/L on day eight. Nowadays patient is in regular treatment with Rituximab.
DISCUSSION
Alemtuzumab is a monoclonal antibody to human CD52 on lymphocytes. It is a highly effective therapy for RRMS treatment. Alemtuzumab is related with some adverse events, including opportunistic infections and autoimmunity. Thyroid disorders, immune thrombocytopenic purpura, nephropathies, and autoimmune hepatitis has been described. Despite previously related autoimmune hepatitis, DILI is an unexpected adverse effect for this medication.
FINAL COMMENTS
We report a case of an acute non-autoimmune hepatitis induced by Alemtuzumab in a patient with RRMS during the first round of treatment. To our knowledge this is the second published report of DILI associated with Alemtuzumab, therefore highlighting the scientific relevance of this case report.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper